Research and Markets: Vital Signs - FDA Clears First 3D Printed Prescription Drug

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/kznn5z/vital_signs_the) has announced the addition of the "Vital Signs The Analyst's Perspective - August 2015 Issue" report to their offering.

This issue of Vital Signs discusses the FDA's clearance of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

The development of innovative orally disintegrating tablet (ODT) form drugs is nothing new. However, the methods by which the oral drugs can be prepared or formulated are new. Technological advances in the 21st century facilitate the ability to make drug products with 3D printers. Aprecia Pharmaceutical's ZipDose technology, facilitated by its 2014 partnership with InVentiv Health, enables the commercialization of ODTs using this unique technology.

Oral drug delivery still has serious unsolved challenges. Patient groups who have difficulty swallowing capsules or tablets benefit greatly from ODT formulations. Medications that are fast-acting (e.g., for pain, diarrhea, migraines, or insomnia), require compliance (e.g., for Alzheimer's, psychosis, schizophrenia, or hypertension), or for pediatric patients (e.g., cold, pain, ADHA) are common uses for ODT medications.

The first ODTs to be developed dissolved in the mouth, but did not taste good or had lots of chalky filler in them. As drug formulation technology improved, the pills have become less bulky. Taste has continued to be a problem for bitter chemical drugs. Micro-encapsulation, spray drying, or adding coatings have allowed the medications to be absorbed lower in the GI tract in a more delayed fashion, avoiding the bad taste.

Key Topics Covered:

1. FDA Clears First 3D Printed Prescription Drug

2. Illumina, Inc. and Investors Form Consumer Genomics Company Helix

3. Response Genetics Enters Into Asset Purchase Agreement with Cancer Genetics

4. Roche's Acquisition Spree Continues with its Purchase of GeneWEAVE for $425 Million

For more information visit http://www.researchandmarkets.com/research/kznn5z/vital_signs_the.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals